An interventional study of PRIME solution in Acute Kidney Injury, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Acute Kidney Injury by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Acute Kidney Injury · Seoul National University Hospital.
Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 9 with no phase, and was the 15th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 18 studies in Acute Kidney Injury by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages up to 7
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,438 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 190 across the 11 interventional studies, 1,099 across the 7 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
1 of the studies in Acute Kidney Injury by Seoul National University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898944Seoul National University HospitalPrognosis and Risk Factors for Acute Kidney Injury | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the occurrence of acute kidney injury (AKI) in inpatients when information from the 'PRIME solution' (AKI prediction program utilizing artificial intelligence) is provided. The main questions it aims to answer are: •[When Artificial intelligence (AI) provides information regarding AKI occurrence prediction within 48 hours, what would change in the physician's behavior?] •[If provided with AI information, what would be the incidence of AKI, severe AKI (stage 2 or 3), kidney replacement therapy, and changes in mortality during hospitalization?] In the case of the intervention group that receives AI information, autonomous treatment is conducted by referring to AI prediction information. Researchers will compare it with a usual-care group that does not receive AI prediction results.
The investigators designed a prospective, investigator-initiated, single-center, single-blinded, randomized controlled study with two experimental groups. A total of 1438 participants with hospitalized patients will be enrolled and randomized into two groups; intervention or usual-care groups. The investigators will apply an AKI prediction model based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician. The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission. The usual-care group does not receive analysis results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission.
Other: PRIME solution
The usual-care group does not receive analysis results. The user-care group continues the existing treatment.
The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
physician's behavior change
Physician's pattern of care changed after receiving AI prediction information The primary category of outcomes was the change in clinicians' behavior, including clinicians' medical treatment patterns, instances of overlooked AKI, and clinicians' consultation patterns. Medical treatment patterns of clinicians were classified into the following 5 categories: Patient assessment, Review of medication, Imaging workup, Monitoring hemodynamic stability, Evaluate furthermore. Overlooked AKI was defined as the absence of a follow-up Scr measurement within 2 weeks after AKI. Consultation to the nephrology division was classified into the following 3 outcomes: no consultation, early consultation, and late consultation. Early consultation was defined as consultation within 3 days from the AKI prediction. Consults issued more than 3 days after the AKI prediction were considered late consultations.
Time frame: From the date of radomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission
incidence of AKI
AKI is defined as any of the following (NotGraded): * Increase in SCr by ≥ 0.3mg/dl (≥26.5umol/l) within 48 hours;or * Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7days; or * Urine volume \< 0.5ml/kg/h for 6hours.
Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission
severe AKI (stage 2 or 3)
stage 2: Serum creatinine (SCr) 2.0-2.9 times baseline or Urine output \< 0.5ml/kg/h for ≥12hours stage 3: Serum creatinine 3.0 times baseline or increase in serum creatinine to ≥ 4.0 mg/dl or initiation of renal replacement therapy or Urine output \< 0.3ml/kg/h for ≥24hours or Anuria for ≥ 12 hours
Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission
renal replacement therapy
Patients who underwent renal replacement therapy
Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission
death
patient who died during hospitalization
Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Dec 2024, 15 months later.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 15 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →